[The pharmacological treatment of digestive endocrine tumors with the somatostatin analog SMS 201-995].

Abstract

Eight patients suffering gastroenteropancreatic apudomas were prospectively treated with subcutaneous SMS 201-995 at a dose of 25-50 mg/12 hours, before breakfast and dinner during two months. Biological and clinical effects were evaluated as well as the possible antitumor effect. In those cases that obtained a clinical and/or biological benefit, treatment was continued uninterruptedly. The results showed that SMS 201-995 is a well tolerated drug which permits ambulatory treatment of patients with GI endocrine tumors being the main objective the reduction of hormone levels and symptom control, not finding in most cases an antitumor effect.

• Authors: M J Varas Lorenzo
• Journal: Revista clinica espanola (Rev Clin Esp) Vol. 188 Issue 1 Pg. 4-6 (Jan 1991) ISSN: 0014-2565 [Print] Spain
• Vernacular Title: Tratamiento farmacológico de los tumores endocrino-digestivos con el análogo de la somatostatina SMS 201-995.
• PMID: 2063026 (Publication Type: Clinical Trial, Comparative Study, English Abstract, Journal Article)

Chemical References

• Octreotide

Topics

• Apudoma (blood, drug therapy)
• Digestive System Neoplasms (blood, drug therapy)
• Humans
• Octreotide (therapeutic use)
• Prospective Studies